Carnitine therapy for the treatment of metabolic syndrome and cardiovascular disease: Evidence and controversies

被引:31
|
作者
Johri, A. M. [1 ]
Heyland, D. K. [2 ,3 ]
Hetu, M. -F. [1 ]
Crawford, B. [1 ]
Spence, J. D. [4 ,5 ]
机构
[1] Queens Univ, Dept Med, Div Cardiol, Cardiovasc Imaging Network, Kingston, ON K7L 2V7, Canada
[2] Queens Univ, Dept Med, Div Community Hlth & Epidemiol, Kingston, ON K7L 2V7, Canada
[3] Queens Univ, Clin Evaluat Res Unit, Kingston, ON K7L 2V7, Canada
[4] Robarts Res Inst, London, ON N6A 5C1, Canada
[5] Univ Western Ontario, London, ON, Canada
关键词
Metabolic syndrome; Diabetes; Atherosclerosis; Cardiovascular disease; Coronary artery disease; Plaque; L-Carnitine; PROPIONYL-L-CARNITINE; LOW-DENSITY-LIPOPROTEIN; ACETYL-L-CARNITINE; PLASMA ADIPONECTIN LEVELS; FATTY-ACID OXIDATION; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; ATHEROSCLEROTIC LESIONS; MICROBIOTA METABOLISM; GLUCOSE-OXIDATION;
D O I
10.1016/j.numecd.2014.03.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As the incidence of metabolic syndrome increases, there is also a growing interest in finding safe and inexpensive treatments to help lower associated risk factors. L-carntine, a natural dietary supplement with the potential to ameliorate atherosclerosis, has been the subject of recent investigation and controversy. A majority of studies have shown benefit of L-C supplementation in the metabolic syndrome or cardiovascular risk factors. However, recent work has suggested that dietary L-C may accelerate atherosclerosis via gut microbiota metabolites, complicating the role of L-C supplementation in health. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:808 / 814
页数:7
相关论文
共 50 条
  • [1] METABOLIC SYNDROME AND CEREBROVASCULAR DISEASE: EVIDENCE IN THEIR TREATMENT
    Rodriguez-Ku, R. J.
    REVISTA DE NEUROLOGIA, 2009, 48 (05) : 255 - 260
  • [2] Cardiovascular metabolic syndrome: mediators involved in the pathophysiology from obesity to coronary heart disease
    Roos, Cornelis J.
    Quax, Paul H. A.
    Jukema, J. Wouter
    BIOMARKERS IN MEDICINE, 2012, 6 (01) : 35 - 52
  • [3] Pathophysiology and Therapeutics of Cardiovascular Disease in Metabolic Syndrome
    Wang, Yabin
    Yu, Qiujun
    Chen, Yundai
    Cao, Feng
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (27) : 4799 - 4805
  • [4] Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
    Zhou, Ji-Yin
    Chan, Lawrence
    Zhou, Shi-Wen
    CURRENT VASCULAR PHARMACOLOGY, 2014, 12 (01) : 136 - 143
  • [5] The metabolic syndrome and cardiovascular disease
    Bonora, E
    ANNALS OF MEDICINE, 2006, 38 (01) : 64 - 80
  • [6] Metabolic Syndrome and Cardiovascular Disease: A Health Challenge
    Gonzalez-Chavez, Antonio
    Alejandro Chavez-Fernandez, Jose
    Elizondo-Argueta, Sandra
    Gonzalez-Tapia, Alonso
    Israel Leon-Pedroza, Jose
    Ochoa, Cesar
    ARCHIVES OF MEDICAL RESEARCH, 2018, 49 (08) : 516 - 521
  • [7] Determinants of Increased Cardiovascular Disease in Obesity and Metabolic Syndrome
    Vazzana, N.
    Santilli, F.
    Sestili, S.
    Cuccurullo, C.
    Davi, G.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (34) : 5267 - 5280
  • [8] Prevalence of metabolic syndrome and cardiovascular disease in a hypertriglyceridemic population
    Ascaso, Juan F.
    Millan, Jesus
    Mateo-Gallego, Rocio
    Ruiz, Antonio
    Suarez-Tembra, M.
    Borrallo, Rosa M.
    Zambon, Daniel
    Gonzalez-Santos, Pedro
    Peres-de-Juan, Miguel
    Ros, Emili
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2011, 22 (02) : 177 - 181
  • [9] Renal disease, the metabolic syndrome, and cardiovascular disease
    Hoy, Wendy E.
    Kondalsamy-Chennakesavan, Srinivas
    McDonald, Stephen
    Wang, Zhiqiang
    ETHNICITY & DISEASE, 2006, 16 (02) : 46 - 51
  • [10] Testosterone, cardiovascular disease and the metabolic syndrome
    Corona, Giovanni
    Rastrelli, Giulia
    Vignozzi, Linda
    Mannucci, Edoardo
    Maggi, Mario
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 25 (02) : 337 - 353